About the Authors
- Paolo Puccetti
-
Affiliation Department of Experimental Medicine, University of Perugia, Perugia, Italy
- Francesca Fallarino
-
Affiliation Department of Experimental Medicine, University of Perugia, Perugia, Italy
- Antoine Italiano
-
Affiliation Department of Medical Oncology, Institut Bergonié, Bordeaux, France
- Isabelle Soubeyran
-
Affiliation Department of Medical Oncology, Institut Bergonié, Bordeaux, France
- Gaetan MacGrogan
-
Affiliation Department of Medical Oncology, Institut Bergonié, Bordeaux, France
- Marc Debled
-
Affiliation Department of Medical Oncology, Institut Bergonié, Bordeaux, France
- Valerie Velasco
-
Affiliation Department of Medical Oncology, Institut Bergonié, Bordeaux, France
- Dominique Bodet
-
Affiliation ImmuSmol, Pessac, France
- Sandrine Eimer
-
Affiliation Histology and Molecular Pathology of Tumors Laboratory EA 2406, University Bordeaux Segalen, Bordeaux, France
- Marc Veldhoen
-
Affiliation Laboratory for Lymphocyte Signalling and Development, The Babraham Institute, Cambridge, United Kingdom
- Georges C. Prendergast
-
Affiliation Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, United states of America
- Michael Platten
-
Affiliations CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany, Department of Neurooncology, University Hospital, Heidelberg, Germany
- Alban Bessede
-
Contributed equally to this work with: Alban Bessede, Gilles J. Guillemin
* E-mail: gilles.guillemin@mq.edu.au (GJG); abessede@immusmol.com (AB)
Affiliation ImmuSmol, Pessac, France
- Gilles J. Guillemin
-
Contributed equally to this work with: Alban Bessede, Gilles J. Guillemin
* E-mail: gilles.guillemin@mq.edu.au (GJG); abessede@immusmol.com (AB)
Affiliations Macquarie University, Faculty of Medicine, Neuroinflammation group, Sydney, New South Wales, Australia, Applied Neurosciences Program, Peter Duncan Neurosciences Research Unit, St Vincent’s Centre for Applied Medical Research, Darlinghurst, New South Wales, Australia
Competing Interests
A. Bessede is CEO of ImmuSmol and is the primary inventor on the patent "Antagonist to an enzyme and/or a metabolite of the kynurenine pathway". The authors have declared that no other competing interests exist.
Author Contributions
Conceived and designed the experiments: AB PP. Performed the experiments: DB FF. Analyzed the data: AI IS GMG MD VV SE. Contributed reagents/materials/analysis tools: MV MP. Wrote the paper: PP GCP AB GJG.